April 23, 2026
STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement
Key Result
Transcatheter aortic valve replacement outcomes improved from 2011 to 2019, with 30-day mortality decreasing from 7.2% to 2.5% and stroke decreasing from 2.75% to 2.3%.
Key Points
- This research aims to present new data on transcatheter aortic valve replacement (TAVR) outcomes, particularly focusing on low-risk patients.
- Data collected from the STS-ACC TVT Registry from 2011 to 2019, including 276,316 patients.
- Focusing on outcomes from 8,395 low-risk patients treated in 2019.
- Analysis of TAVR data included hospital stay duration, mortality rates, and patient-reported outcomes.
- 30-day mortality decreased from 7.2% to 2.5%, representing a significant improvement in patient survival.
- Stroke rates reduced from 2.75% to 2.3%, indicating enhanced safety profiles over time.
- Pacemaker need remained stable at around 10.8%, highlighting an area requiring further study.
Study Design
Type
Observational (n=276,316)
Multicenter
Yes
Structured PICO
What are the real-world trends in procedural characteristics and clinical outcomes for patients undergoing TAVR in the United States?
P
Population
276,316 patients undergoing transcatheter aortic valve replacement (TAVR) at sites in all U.S. states from 2011 to 2019, ranging from extreme- to low-risk.
I
Intervention
Transcatheter aortic valve replacement (TAVR)
O
Outcome
Trends in procedural volumes, access routes, hospital stay, discharge status, 30-day mortality, stroke, pacemaker need, and 1-year patient-reported outcomeshard clinical
The STS-ACC TVT Registry demonstrates a massive growth in TAVR volume across all risk categories in the US, accompanied by significant reductions in 30-day mortality and stroke rates from 2011 to 2019.
Main Result
Absolute Event Rate: 2.5% vs 7.2%
Abstract
The STS-ACC TVT Registry (Society of Thoracic Surgeons-American College of Cardiology Transcatheter Valve Therapy Registry) from 2011 to 2019 has collected data on 276,316 patients undergoing transcatheter aortic valve replacement (TAVR) at sites in all U.S. states. Volumes have increased every year, exceeding surgical aortic valve replacement in 2019 (72,991 vs. 57,626), and it is now performed in all U.S. states. TAVR now extends from extreme- to low-risk patients. This is the first presentation on 8,395 low-risk patients treated in 2019. In 2019, for the entire cohort, femoral access increased to 95.3%, hospital stay was 2 days, and 90.3% were discharged home. Since 2011, the 30-day mortality rate has decreased (7.2% to 2.5%), stroke has started to decrease (2.75% to 2.3%), but pacemaker need is unchanged (10.9% to 10.8%). Alive with acceptable patient-reported outcomes is achieved in 8 of 10 patients at 1 year. The Registry is a national resource to improve care and analyze TAVR's evolution. Real-world outcomes, site performance, and the impact of coronavirus disease 2019 will be subsequently studied. (STS/ACC Transcatheter Valve Therapy Registry TVT Registry; NCT01737528).
Expert Takes2 quotes
1/2
“The TVT Registry will capture and house patient demographics, procedure details, and facility and physician information. This standardized, evidence based data source will offer much insight into clinical practice patterns and patient outcomes. I believe this coordinated effort optimizes patient safety and ensures the appropriate use of TAVR therapy.”
Michael J. Mack, Cardiothoracic surgeon, Baylor Scott and White HealthBaylor Scott and White Healthauto_pipelineView source
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Expert Takes
Authors
J
John D. Carroll
Interventional Cardiology
Michael J. Mack
Chandigarh University
Sreekanth Vemulapalli
Structural Heart Disease
Journals
Journal of the American College of Cardiology
Actions
Institutions
Harvard University
University of Michigan
University of Pennsylvania
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...